Galectin Therapeutics Inc. (GALT)

[JERZYATP1]

In my opinion altho you have previously shown a handsome capacity for rationality, your current emotional distortions are driving you off the rails.
As to your reaction to the recent poster presentations at the Liver Meeting, count me as one person who "doesn't get it" (ie. doesn't get your case). Like it or not GALT's work is science-based technology. In the relatively short-term it has been in the company's interest to get a grip on currently putative non-invasive methods for fibrosis diagnosis. The FX trial found that the LiverMultiScan has too much scatter to be useful. You are quick to jump on this as a failure, when for those in the trenches it's a valuable "success" in strategic knowledge acquisition. If you don't get this you don't get that science and technology work by trial and error.
You're right that GALT is not a non-invasive diagnosis venture per se. But you are discounting that GALT's prime thrust (CX trial) prudently employs invasive diagnosis (HVPG top line,
biopsy). The FX trial is understandable as a supplemental scoping of the complex diagnosis landscape that confronts all companies into fibrosis.
Had the FX trial been a "success" (to you) you'd be giddy regardless of any conceptual demerit or latent risk to shareholder value.
Conclusion: you can rest easy and put your corrosiveness behind you as GALT does its work towards CX, as well as other projects.